for Journals by Title or ISSN
for Articles by Keywords
help
Followed Journals
Journal you Follow: 0
 
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover
Nature Reviews Drug Discovery
Journal Prestige (SJR): 10.106
Citation Impact (citeScore): 10
Number of Followers: 338  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1474-1776 - ISSN (Online) 1474-1784
Published by NPG Homepage  [144 journals]
  • Genome editing to 're-write' wrongs
    • Genome editing to 're-write' wrongs

      Genome editing to 're-write' wrongs, Published online: 22 June 2018; doi:10.1038/nrd.2018.91

      The NIH has launched the Somatic Cell Genome Editing (SCGE) programme to accelerate the development of safer and more effective genome-editing therapeutics.Genome editing to 're-write' wrongs, Published online: 2018-06-22; doi:10.1038/nrd.2018.912018-06-22
      DOI: 10.1038/nrd.2018.91
       
  • Stroke: Opening the therapeutic window
    • Stroke: Opening the therapeutic window

      Stroke: Opening the therapeutic window, Published online: 15 June 2018; doi:10.1038/nrd.2018.98

      Stroke: Opening the therapeutic windowStroke: Opening the therapeutic window, Published online: 2018-06-15; doi:10.1038/nrd.2018.982018-06-15
      DOI: 10.1038/nrd.2018.98
       
  • The promise and challenges of immune agonist antibody development in
           cancer
    • The promise and challenges of immune agonist antibody development in cancer

      The promise and challenges of immune agonist antibody development in cancer, Published online: 15 June 2018; doi:10.1038/nrd.2018.75

      Co-stimulatory receptors mediate the anticancer immune response. This Review discusses the current efforts in targeting co-stimulatory receptors with agonist antibodies and the landscape of agonist antibodies in clinical development for cancer treatment.The promise and challenges of immune agonist antibody development in cancer, Published online: 2018-06-15; doi:10.1038/nrd.2018.752018-06-15
      DOI: 10.1038/nrd.2018.75
       
  • The market for oral anticoagulants
    • The market for oral anticoagulants

      The market for oral anticoagulants, Published online: 15 June 2018; doi:10.1038/nrd.2018.89

      This article discusses the market for oral anticoagulants, and how therapies in development and antidotes to existing drugs could affect the therapeutic landscape.The market for oral anticoagulants, Published online: 2018-06-15; doi:10.1038/nrd.2018.892018-06-15
      DOI: 10.1038/nrd.2018.89
       
  • Infectious diseases: The painful path to avoiding the immune system
    • Infectious diseases: The painful path to avoiding the immune system

      Infectious diseases: The painful path to avoiding the immune system, Published online: 15 June 2018; doi:10.1038/nrd.2018.100

      Infectious diseases: The painful path to avoiding the immune systemInfectious diseases: The painful path to avoiding the immune system, Published online: 2018-06-15; doi:10.1038/nrd.2018.1002018-06-15
      DOI: 10.1038/nrd.2018.100
       
  • Cancer: Re-educating tumour-associated macrophages with nanoparticles
    • Cancer: Re-educating tumour-associated macrophages with nanoparticles

      Cancer: Re-educating tumour-associated macrophages with nanoparticles, Published online: 15 June 2018; doi:10.1038/nrd.2018.102

      Cancer: Re-educating tumour-associated macrophages with nanoparticlesCancer: Re-educating tumour-associated macrophages with nanoparticles, Published online: 2018-06-15; doi:10.1038/nrd.2018.1022018-06-15
      DOI: 10.1038/nrd.2018.102
       
  • Overcoming the legal and regulatory barriers to drug repurposing
    • Overcoming the legal and regulatory barriers to drug repurposing

      Overcoming the legal and regulatory barriers to drug repurposing, Published online: 08 June 2018; doi:10.1038/nrd.2018.92

      Drug repurposing has been proposed as a strategy to develop new therapies that has fewer risks, lower costs and shorter timelines than developing completely new drugs. However, the potential of this strategy has not been as widely realized as hoped, in part owing to legal and regulatory barriers. Here, we highlight these barriers and consider how they could be overcome.Overcoming the legal and regulatory barriers to drug repurposing, Published online: 2018-06-08; doi:10.1038/nrd.2018.922018-06-08
      DOI: 10.1038/nrd.2018.92
       
  • Cryo-EM in drug discovery: achievements, limitations and prospects
    • Cryo-EM in drug discovery: achievements, limitations and prospects

      Cryo-EM in drug discovery: achievements, limitations and prospects, Published online: 08 June 2018; doi:10.1038/nrd.2018.77

      Recent technological advances with cryo-electron microscopy (cryo-EM) — a biophysical technique that can be used to determine the structure of biological macromolecules and assemblies — have raised hopes that it might soon become an important tool for drug discovery, particularly for 'intractable' targets that are still not accessible to analysis by X-ray crystallography. This article describes these advances and critically assesses their relevance for drug discovery.Cryo-EM in drug discovery: achievements, limitations and prospects, Published online: 2018-06-08; doi:10.1038/nrd.2018.772018-06-08
      DOI: 10.1038/nrd.2018.77
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.198.170.159
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-